141
Participants
Start Date
August 7, 2024
Primary Completion Date
February 22, 2027
Study Completion Date
February 22, 2027
M9466
Participants will be administered M9466 orally.
Tuvusertib
Participants will be administered Tuvusertib orally.
Abiraterone acetate
Participants will be administered with Abiraterone acetate orally.
Prednisone/Prednisolone
Participants will be administered with prednisone/prednisolone orally.
RECRUITING
NEXT Oncology - PARENT, New York
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Cancer Research SA, Adelaide
RECRUITING
GenesisCare North Shore (Oncology), St Leonards
RECRUITING
Harasanshin Hospital, Fukuoka
RECRUITING
National Cancer Center Hospital East - Dept of Experimental Therapeutics, Kashiwa-shi
RECRUITING
Cancer Institute Hospital of JFCR, Kōtoku
RECRUITING
NHO Kumamoto Medical Center - Dept of Urology, Kumamoto
RECRUITING
Seoul National University Bundang Hospital, Seongnam
RECRUITING
Asan Medical Center, Seoul
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Severance Hospital, Yonsei University Health System - Division of Infectious Diseases, Seoul
RECRUITING
Hospital HM Nou Delfos - START Barcelona, Barcelona
RECRUITING
Hospital Universitari Vall d'Hebron - Oncology Dept., Barcelona
RECRUITING
ICO l'Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia, Barcelona
RECRUITING
Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica, Madrid
RECRUITING
Hospital Universitario 12 de Octubre - Servicio de Oncologia, Madrid
RECRUITING
Hospital Universitario Fundacion Jimenez Diaz - START Madrid FJD - Oncology Phase I, Madrid
RECRUITING
NEXT Madrid - Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY